Given this payment schedule and ongoing clinical trials for Marqibo, it is unlikely any payments can occur soon. The following article suggests the first milestone is reached in 2018 according to the author's sales model.
I cannot remember how many CVRs were issued but if anyone has the figure off-hand, then you can work out a single CVR payment for the $5million payment. I am not throwing my CVRs away but not counting on getting my investment back. On the other hand, I have not been following the Marqibo R&D investments by Spectrum as the author suggests to see if there is more potential here. All we can do is wait otherwise.
The Spectrum report on Aug 6th shows Marqibo quarterly sales at 28% of the first milestone target if this sales level was sustained over any year: MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $2.1 million
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.